|Bid||155.20 x 1000|
|Ask||164.68 x 900|
|Day's range||153.96 - 159.28|
|52-week range||117.64 - 186.22|
|Beta (5Y monthly)||0.87|
|PE ratio (TTM)||N/A|
|Earnings date||21 Feb 2022 - 25 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||202.00|
With the S&P 500 in bear market territory (a drop of 20% or more from its most recent highs) and persistent geopolitical and economic problems, it's not clear that the end of these troubles is in sight. Eli Lilly's stock is up by an impressive 17% since the beginning of the year. While the company has delivered solid financial results, perhaps the forward-looking market is more excited about its prospects.
JAZZ's phase III study evaluating nabiximols oromucosal spray for clinical measures of spasticity in multiple sclerosis patients fails to meet the primary endpoint.
Regardless of how long you've been investing in the stock market, this has been a challenging year. Since all three major U.S. indexes hit their respective record-closing highs between mid-November and the first week of January, two of them have fallen into a bear market -- the broad-based S&P 500 and technology-dependent Nasdaq Composite. Although a plunging stock market can be unnerving and tug on investor's emotions, double-digit percentage drawdowns in the major indexes are a perfectly normal part of the investing cycle.